Poststroke Functional Outcomes Are Improved by Cytoprotective Therapy with Edaravone Dexborneol.

Published Date: 29 Feb 2024

The main finding indicated that edaravone dexborneol had a highly significant impact on good functional outcome, which was measured at 90 days postrandomization using scores of 0 (no symptoms) or 1 (some symptoms) on the standard modified Rankin scale.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot